Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:02:28.940Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:02:28.940Z.
Quote observation: 2026-10-06T15:00:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
FORWARD PE RATIO
N/A
Electra Therapeutics Inc.
Market Cap
$198.76M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Electra Therapeutics Inc. (ETRA) | $198.76M | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.58M | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $190.17M | N/A |
| Alector, Inc. (ALEC)vs › | $209.84M | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $213.19M | N/A |
| Compugen Ltd. (CGEN)vs › | $214.16M | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $214.19M | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $183.14M | 1.00 |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 18.69 |
| Canton Strategic Holdings Inc (CNTN)vs › | $181.62M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
